Pimasertib - Day One Biopharmaceuticals
Alternative Names: AS-703026; EMD-1036239; MSC 1936369; MSC 1936369B; MSC1936369ALatest Information Update: 01 Feb 2024
At a glance
- Originator Santhera Pharmaceuticals
- Developer Day One Biopharmaceuticals; Merck Serono; Sanofi
- Class Amides; Aminopyridines; Antineoplastics; Iodobenzenes; Small molecules
- Mechanism of Action Apoptosis stimulants; MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Discontinued Colorectal cancer; Haematological malignancies; Malignant melanoma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 17 Jan 2024 Australian & New Zealand Children's Haematology/Oncology Group plans a phase I/II trial for the treatment of Cancer (In children, In adults, Second-line or greater therapy) in Australia and Canada (PO) in March 2024 (NCT06208657)
- 08 Feb 2022 Day One Biopharmaceuticals has patents pending for pimasertib in combination with tovorafenib for treating cancer in US
- 17 Sep 2021 Phase-I clinical trials in Solid tumours in USA (PO) (Day One Biopharmaceuticals pipeline, September 2021)